title: [Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY].
abstract: Objective:This analysis was performed to evaluate the efficacy in stroke prevention and safety of dabigatran in Chinese nonvalvular atrial fibrillation(NVAF) patients enrolled in RE-LY trial.Methods:RE-LY was an prospective, open-label, randomized, multicenter study. From March 2006 to March 2009, 541 atrial fibrillation patients at risk of stroke were recruited from 13 medical centers in China. Patients randomly received, in a blinded fashion, fixed doses of dabigatran-110 mg or 150 mg twice daily or, in an unblinded fashion, adjusted-dose warfarin. The primary efficacy endpoint was stroke or systemic embolism. The primary safety endpoint was major bleeding.Results:The incidence of stroke in the Chinese subpopulation was 1.94% per year(7 cases) in the group that received 110 mg of dabigatran (dabigatran 110) and 1.10% per year(4 cases) in the group that received 150 mg of dabigatran (dabigatran 150), as compared with 2.87% per year (10 cases) in warfarin group . Incidence of ischemic stroke was 1.11% per year(4 patients) in dabigatran 110 group, 0.82% per year(3 cases) in dabigatran 150 group and 2.01% per year(7 patients) in warfarin group. Incidence of hemorrhagic stroke was 0.28% per year(1 case) in dabigatran 110 group, 0.27% per year(1 case) in dabigatran 150 group and 0.57% per year(2 cases) in warfarin group. All-cause mortality was similar among the three treatment groups: 3.33% per year(12 cases) in dabigatran 110, 2.19% per year(8 cases) in dabigatran 150 and 2.58% per year(9 cases) in warfarin group. Incidence of major bleeding event was 0.56% per year(2 cases) in both dabigatran groups, as compared with 1.43% per year(5 cases) in warfarin group. Gastrointestinal disorders such as dyspepsia occurred in 12.8% patients of both dabigatran groups, and in 5.6% patients of warfarin group.Conclusions:Despite the descriptive statistical analysis in nature of present study due to the limited number of subjects, our subgroup analysis implies that like warfarin, dabigatran is efficacious and safe for thromboembolism prevention in Chinese patients with atrial fibrillation at risk of stroke. Clinical Trail Registry National Institutes of Health(http: //www.clinicaltrials.gov), CT00262600.
authors.affiliation: Emergency and Intensive Care Center, Cardiovascular Department, Fuwai Hospital, Chinese Academy Of Medical Sciences and Peking Union Medical College, Beijing 10037, China.
authors.forename: X
authors.initials: X
authors.lastname: Gao
authors.forename: Y M
authors.initials: YM
authors.lastname: Yang
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: Y
authors.initials: Y
authors.lastname: Dai
authors.forename: H Q
authors.initials: HQ
authors.lastname: Tan
mesh_terms: D000925:Anticoagulants; D044466:Asian People; D001281:Atrial Fibrillation; D001562:Benzimidazoles; D000069604:Dabigatran; D006801:Humans; D011446:Prospective Studies; D020521:Stroke / Q000517:prevention & control*; D014859:Warfarin
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D014859:Warfarin; D000069604:Dabigatran